Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Haim Erder

Showing results (21-30 of 61) with videos related to

Pageof 7
Sort By:
Journal of Medical Economics|August 14, 2013
Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adultsJuliana Setyawan, Paul Hodgkins, Annie Guérin, et al.
Journal of Health Economics and Outcomes Research|September 4, 2023
Preferences for Attention-Deficit/Hyperactivity Disorder (ADHD) Non-Stimulant Treatment Characteristics Among Children and Adolescents With ADHD and Their CaregiversEmuella Flood, Kavita Gajria, Vanja Sikirica, et al.
Attention Deficit and Hyperactivity Disorders|August 24, 2014
Relationship between symptom impairment and treatment outcome in children and adolescents with attention-deficit/hyperactivity disorder: a physician perspectiveJuliana Setyawan, Moshe Fridman, Paul Hodgkins, et al.
Managed Care (Langhorne, Pa.)|February 16, 2012
Treatment persistence & health care costs of adult MDD patients treated with escitalopram vs. citalopram in a medicaid populationEric Q Wu, Rym Ben-Hamadi, Mei Lu, et al.
Current Medical Research and Opinion|May 24, 2007
Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezilDerek Weycker, Charu Taneja, John Edelsberg, et al.
Pharmacoeconomics|July 14, 2012
Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescentsVanja Sikirica, M Haim Erder, Jipan Xie, et al.
Journal of Medical Economics|April 30, 2013
Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysisJuliana Setyawan, Paul Hodgkins, Annie Guérin, et al.
Journal of Medical Economics|May 28, 2010
Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasonsEric Q Wu, Rym Ben-Hamadi, Andrew P Yu, et al.
CNS Spectrums|August 19, 2016
Estimating minimal important differences for several scales assessing function and quality of life in patients with attention-deficit/hyperactivity disorderPaul Hodgkins, Andrew Lloyd, M Haim Erder, et al.
Pharmacoepidemiology and Drug Safety|May 4, 2012
Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorderJames Signorovitch, M Haim Erder, Jipan Xie, et al.
Pageof 7

Showing results (21-30 of 61) with videos related to

Sort By:
Pageof 7
Journal of Medical Economics|August 14, 2013
Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adultsJuliana Setyawan, Paul Hodgkins, Annie Guérin, et al.
Journal of Health Economics and Outcomes Research|September 4, 2023
Preferences for Attention-Deficit/Hyperactivity Disorder (ADHD) Non-Stimulant Treatment Characteristics Among Children and Adolescents With ADHD and Their CaregiversEmuella Flood, Kavita Gajria, Vanja Sikirica, et al.
Attention Deficit and Hyperactivity Disorders|August 24, 2014
Relationship between symptom impairment and treatment outcome in children and adolescents with attention-deficit/hyperactivity disorder: a physician perspectiveJuliana Setyawan, Moshe Fridman, Paul Hodgkins, et al.
Managed Care (Langhorne, Pa.)|February 16, 2012
Treatment persistence & health care costs of adult MDD patients treated with escitalopram vs. citalopram in a medicaid populationEric Q Wu, Rym Ben-Hamadi, Mei Lu, et al.
Current Medical Research and Opinion|May 24, 2007
Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezilDerek Weycker, Charu Taneja, John Edelsberg, et al.
Pharmacoeconomics|July 14, 2012
Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescentsVanja Sikirica, M Haim Erder, Jipan Xie, et al.
Journal of Medical Economics|April 30, 2013
Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysisJuliana Setyawan, Paul Hodgkins, Annie Guérin, et al.
Journal of Medical Economics|May 28, 2010
Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasonsEric Q Wu, Rym Ben-Hamadi, Andrew P Yu, et al.
CNS Spectrums|August 19, 2016
Estimating minimal important differences for several scales assessing function and quality of life in patients with attention-deficit/hyperactivity disorderPaul Hodgkins, Andrew Lloyd, M Haim Erder, et al.
Pharmacoepidemiology and Drug Safety|May 4, 2012
Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorderJames Signorovitch, M Haim Erder, Jipan Xie, et al.
Pageof 7